ACTTIVAC A Phase 2a Randomised Clinical Trial to Identify the Optimal Dose of the Thermostable ID93+GLA-SE Tuberculosis Vaccine for Further Clinical Evaluation and Local Manufacture in Africa
- Coordinator
- Stichting Tuberculosis Vaccine Initiative, Netherlands
- Runs
- 1 August 2026 to 31 July 2030
- Status
- Running
- EU funding
- €11.9m
- Total cost
- €14.4m
- Partners
- 7 organisations in 4 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101248955
What the project is doing
In the project's own words, from its summary on CORDIS.
The proposed project ACTTIVAC’s objectives are 1. Manufacture and co-lyophilisation of the ID93 antigen and GLA-SE adjuvant according to Good Manufacturing Practices, ensuring quality and regulatory compliance, 2. Generation of safety and immunogenicity data in humans to identify the optimal dose of the lyophilised ID93+GLA-SE TB vaccine for Mycobacterium tuberculosis (MTB)-sensitised adolescents and adults, in preparation for a planned phase 2b efficacy trial in this population, 3.
Implementation of clinical research capacity development to contribute to the development of a sustainable clinical research workforce in Africa by strengthening local capacity in clinical trial operations, TB vaccinology and product development, and laboratory proficiency, 4. Technology transfer of the adjuvant production to enable local manufacture of clinical trial material in TB-endemic African countries to ensure sustainable vaccine supply post-licensure and 5.
Evaluation of the thermostability of the lyophilised ID93+GLA-SE under field conditions to ensure that the vaccine is thermostable when stored at room temperature for at least 6 months. The proposed project will contribute to Global Health EDCTP3’s overall goals of accelerating clinical evaluation of interventions for poverty-related infectious diseases in Sub-Saharan Africa (SSA) and building local research capacity.
More specifically, the proposed project aligns with the EDCTP3’s 2025 Work Programme to develop vaccines for reducing TB disease burden in Sub-Saharan Africa through research and innovation. The proposed project will deliver three expected outcomes for the 2025 Work Programme: 1. Evidence of immunogenicity and safety for the optimal dose of the lyophilised ID93+GLA-SE vaccine candidate, 2. Clinical data on this prophylactic TB vaccine candidate for MTB-sensitised adolescents and adults and 3.
Data on dosing and regimen of this lyophilised TB vaccine candidate for use in future vaccination
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Stichting Tuberculosis Vaccine Initiative | Lelystad | Netherlands | Coordinator |
| Obafemi Awolowo University | Ile Ife | NG | Participant |
| Access to Advanced Health (UK) LTD | London | United Kingdom | Participant |
| Afrigen Biologics Ltd | Cape Town | South Africa | Participant |
| Bioinformatico (pty) Ltd | Johannesburg | South Africa | Participant |
| The Aurum Institute Npc | Isando | South Africa | Participant |
| University of Cape Town | Rondebosch | South Africa | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI